New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
05:52 EDTTSROTESARO price target raised to $51 from $42 at Citigroup
Citigroup raised its price target for TESARO shares to $51 citing the company's expanded immuno-oncology pipeline following its license agreement with AnaptysBio. Citi keeps a Buy rating on the stock, saying shares remain compelling.
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 12, 2015
08:24 EDTTSROTESARO expands niraparib clinical program, provides update on FY15 milestones
TESARO provided an update on its late-stage programs. New trial of niraparib for the treatment of ovarian cancer to begin in Q1. HRD assay to be incorporated into Phase 3 NOVA trial of niraparib in ovarian cancer. Initial Phase 3 data from NOVA is expected to become available in 2015. FDA PDUFA action date for oral rolapitant is September 4, 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use